Information Provided By:
Fly News Breaks for November 15, 2019
ZSAN
Nov 15, 2019 | 07:03 EDT
Cantor Fitzgerald analyst Charles Duncan halved his price target for Zosano Pharma to $6 from $12 following the company's Q3 results but reiterates an Overweight rating on the shares. The company ended the period with cash of $6.5M, and management stated that it intends to bring in additional capital by the end of 2019 through equity and/or non-dilutive sources to fund operations through "value-creating" milestones in 2020, Duncan tells investors in a post-earnings research note.
News For ZSAN From the Last 2 Days
There are no results for your query ZSAN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.